
|Articles|September 1, 2018
- Pharmaceutical Executive-09-01-2018
- Volume 38
- Issue 9
Pharmaceutical Executive, September 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Executive September 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 7 years ago
Paul Perreault: The Global CEOover 7 years ago
Specialty Pharma’s Move to Mainstreamover 7 years ago
Specialty Product Launch Insightsover 7 years ago
Beyond Big Data: Meeting the Specialty Marketing Challengeover 7 years ago
Specialty Focus: Tackling Rare Mutation in CFover 7 years ago
The ‘Spare-No-Expense’ Alternativeover 7 years ago
Pharm Exec's 17th Annual Industry Auditover 7 years ago
Specialty Supply Chain Decisionsover 7 years ago
FDA Struggles to Advance Biosimilarsover 7 years ago
Country Report: UKNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Preview: Roche’s Refresh
2
Pharmaceutical Executive Daily: Nine New Additions to TrumpRx
3
AstraZeneca Reaches $2 Billion License Agreement with Jacobio Pharma for Pan-KRAS Inhibitor
4
JP Morgan 2026 Preview: Eli Lilly Seeks Bounce Back
5



